Literature DB >> 7943375

Basic FGF enhances endothelium-dependent relaxation of the collateral-perfused coronary microcirculation.

F W Sellke1, S Y Wang, M Friedman, K Harada, E R Edelman, W Grossman, M Simons.   

Abstract

The effect of chronic, periadventitial administration of basic (b) fibroblast growth factor (FGF) on endothelial dysfunction in the collateral-dependent and normally perfused coronary microcirculation was examined. Ameroid constrictors were placed on the proximal left circumflex coronary artery (LCX) in 23 pigs. In 11 pigs, bFGF was released from calcium alginate microcapsules into the perivascular space of the proximal left anterior descending coronary artery (LAD) and LCX. After 5-8 wk, coronary arterial microvessels (80-170 microns) were studied in a pressurized (40 mmHg) no-flow state with video microscopy. Receptor-mediated endothelium-dependent relaxations to ADP and serotonin were reduced while contraction to acetylcholine was enhanced in the collateral-dependent LCX microvessels of non-bFGF-treated control hearts. Relaxation of vessels to the non-receptor-mediated, endothelium-dependent agent A-23187; endothelium-independent relaxation to nitroprusside; and contraction to KCl were similar in all groups. Chronic treatment with bFGF normalized responses to ADP, serotonin, and acetylcholine in the collateral-dependent LCX region but had no effect on the responses of vessels in the normally perfused LAD region. Arteriolar density in the collateral-perfused LCX region of bFGF-treated hearts was markedly increased (4-fold compared with that in untreated hearts, suggesting a link between the angiogenic effect of bFGF and its action on endothelial preservation. Thus the periadventitial, sustained delivery of bFGF preserves receptor-mediated, endothelium-dependent responses in the collateral-dependent LCX region but has no effect on responses of microvessels in the normally perfused LAD region or on non-receptor-mediated endothelium-dependent relaxation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7943375     DOI: 10.1152/ajpheart.1994.267.4.H1303

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  11 in total

1.  Therapeutic Angiogenesis for Coronary Artery Disease.

Authors:  Tanveer A. Khan; Frank W. Sellke; Roger J. Laham
Journal:  Curr Treat Options Cardiovasc Med       Date:  2002-02

Review 2.  Angiogenesis and vasculogenesis in treatment of cardiovascular disease.

Authors:  A Rivard; J M Isner
Journal:  Mol Med       Date:  1998-07       Impact factor: 6.354

Review 3.  Angiogenesis and the heart: therapeutic implications.

Authors:  M D Hariawala; F W Sellke
Journal:  J R Soc Med       Date:  1997-06       Impact factor: 5.344

Review 4.  Microvascular repair: post-angiogenesis vascular dynamics.

Authors:  Amanda J LeBlanc; Laxminarayanan Krishnan; Christopher J Sullivan; Stuart K Williams; James B Hoying
Journal:  Microcirculation       Date:  2012-11       Impact factor: 2.628

5.  5-HT causes splanchnic venodilation.

Authors:  Bridget M Seitz; Hakan S Orer; Teresa Krieger-Burke; Emma S Darios; Janice M Thompson; Gregory D Fink; Stephanie W Watts
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-06-16       Impact factor: 4.733

Review 6.  Angiogenesis in cardiovascular disease: current status and therapeutic potential.

Authors:  F W Sellke; M Simons
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

7.  Downstream exposure to growth factors causes elevated velocity and dilation in arteriolar networks.

Authors:  Melissa K Georgi; Anthony M Dewar; Mary D Frame
Journal:  J Vasc Res       Date:  2010-07-06       Impact factor: 1.934

Review 8.  Oh, the places you'll go! My many colored serotonin (apologies to Dr. Seuss).

Authors:  Stephanie W Watts
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-09-23       Impact factor: 4.733

9.  Coronary microvascular dysfunction in the setting of chronic ischemia is independent of arginase activity.

Authors:  Neel R Sodha; Munir Boodhwani; Richard T Clements; Jun Feng; Shu Hua Xu; Frank W Sellke
Journal:  Microvasc Res       Date:  2007-08-16       Impact factor: 3.514

10.  Myocardial protection by nanomaterials formulated with CHIR99021 and FGF1.

Authors:  Chengming Fan; Yasin Oduk; Meng Zhao; Xi Lou; Yawen Tang; Danielle Pretorius; Mani T Valarmathi; Gregory P Walcott; Jinfu Yang; Philippe Menasche; Prasanna Krishnamurthy; Wuqiang Zhu; Jianyi Zhang
Journal:  JCI Insight       Date:  2020-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.